Authors: Heath, EI O'Reilly, S Humphrey, R Sundaresan, P Donehower, RC Sartorius, S Kennedy, MJ Armstrong, DK Carducci, MA Sorensen, JM Kumor, K Kennedy, S Grochow, LB

Citation: Ei. Heath et al., Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors, CANC CHEMOT, 48(4), 2001, pp. 269-274

Authors: Rowinsky, EK Humphrey, R Hammond, LA Aylesworth, C Smetzer, L Hidalgo, M Morrow, M Smith, L Garner, A Sorensen, JM Von Hoff, DD Eckhardt, SG

Citation: Ek. Rowinsky et al., Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patientswith solid malignancies, J CL ONCOL, 18(1), 2000, pp. 178-186

Authors: Sorensen, JM Katsiotis, ST

Citation: Jm. Sorensen et St. Katsiotis, Parameters influencing the yield and composition of the essential oil fromCretan Vitex agnus-castus fruits, PLANTA MED, 66(3), 2000, pp. 245-250

Authors: Grem, JL Sorensen, JM Cullen, E Takimoto, CH Steinberg, SM Chen, AP Hamilton, JM Arbuck, SG McAtee, N Lawrence, D Goldspiel, B Johnston, PG Allegra, CJ

Citation: Jl. Grem et al., A phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors, CLIN CANC R, 5(9), 1999, pp. 2381-2391